Goodman-Meza David, Beymer Matthew R, Kofron Ryan M, Amico K Rivet, Psaros Christina, Bushman Lane R, Anderson Peter L, Bolan Robert, Jordan Wilbert C, Rooney James F, Wohl Amy R, Landovitz Raphael J
a Division of Infectious Diseases, David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.
b Health and Mental Health Services, Los Angeles LGBT Center , Los Angeles , CA , USA.
AIDS Care. 2019 Oct;31(10):1228-1233. doi: 10.1080/09540121.2019.1595523. Epub 2019 Mar 20.
PrEP's potential benefit for men who have sex with men (MSM) who use stimulants may be limited by adherence or prescriber willingness to recommend PrEP due to concerns of non-compliance. Using data from PATH-PrEP, a 48-week study evaluating PrEP for MSM in Los Angeles, we modeled an interaction between stimulant use and condomless sex with multiple partners (CAS-MP) on prevention-effective dried blood spot tenofovir-diphosphate concentrations. At week 4, participants reporting stimulant use and CAS-MP had a decreased odds of prevention-effective adherence compared to non-stimulant use and non-CAS-MP (AOR 0.15, 95% CI 0.04-0.57). From week 4-48, participants reporting stimulant use and CAS-MP had increased odds of prevention-effective adherence (AOR 1.06 per week, 95%CI 1.01-1.12). Participants reporting CAS-MP without stimulant use had no significant change in prevention-effective adherence (AOR 0.99 per week, 95%CI 0.96-1.02). Stimulant use moderated the association of CAS-MP on prevention-effective PrEP adherence over time.
J Acquir Immune Defic Syndr. 2025-2-1
Emerg Infect Dis. 2018-12
Antimicrob Agents Chemother. 2017-12-21
J Acquir Immune Defic Syndr. 2017-12-15
AIDS. 2017-3-13
J Acquir Immune Defic Syndr. 2017-1-1